Antiviral effect of mefloquine on feline calicivirus in vitro

Veterinary Microbiology

Volumn 176, Issue 3-4, 2015, Pages 370-377

  McDonagh, Phillip ^a   Sheehy, Paul A ^a   Fawcett, Anne ^a   Norris, Jacqueline M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antiviral; Cats; Feline calicivirus; Mefloquine

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; INTERFERON; MEFLOQUINE; RECOMBINANT FELINE OMEGA INTERFERON; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; INTERFERON OMEGA 1; OXAZINE DERIVATIVE; RESAZURIN; VIRUS VACCINE; XANTHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CALICIVIRUS INFECTION; CELL ACTIVITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; IC50; IN VITRO STUDY; NONHUMAN; REDUCTION KINETICS; VESIVIRUS; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; AUSTRALIA; CALICIVIRIDAE INFECTIONS; CAT; CAT DISEASES; DRUG COMBINATION; DRUG EFFECTS; FELINE CALICIVIRUS; VETERINARY; VIROLOGY;

CALICIVIRIDAE; FELIDAE; FELINE CALICIVIRUS; FELIS CATUS;

ANIMALS; ANTIVIRAL AGENTS; AUSTRALIA; CALICIVIRIDAE INFECTIONS; CALICIVIRUS, FELINE; CAT DISEASES; CATS; DRUG THERAPY, COMBINATION; IN VITRO TECHNIQUES; INHIBITORY CONCENTRATION 50; INTERFERON TYPE I; MEFLOQUINE; OXAZINES; VIRAL VACCINES; XANTHENES;

EID: 84924590359     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2015.02.007     Document Type: Article

References (29)

1. Brickelmaier M., Lugovskoy A., Kartikeyan R., Reviriego-Mendoza M.M., Allaire N., Simon K., Frisque R.J., Gorelik L. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob. Agents Chemother. 2009, 53:1840-1849.
2. Court M.H. Feline drug metabolism and disposition: pharmacokinetic evidence for species differences and molecular mechanisms. Vet. Clin. North Am.: Small Anim. Pract. 2013, 43:1039.
3. Coyne K.P., Christley R.M., Pybus O.G., Dawson S., Gaskell R.M., Radford A.D. Large scale spatial and temporal genetic diversity of feline calicivirus. J. Virol. 2012.
4. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436:967-972.
5. Ferraris O., Kessler N., Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 2005, 68:43-48.
6. Fulton R.W., Burge L.J. Susceptibility of feline herpesvirus 1 and a feline calicivirus to feline interferon and recombinant human leukocyte interferons. Antimicrob. Agents Chemother. 1985, 28:698-699.
7. Glaumann H., Motakefi A.M., Jansson H. Intracellular distribution and effect of the antimalarial drug mefloquine on lysosomes of rat liver. Liver 1992, 12:183-190.
8. Glenn M., Radford A.D., Turner P.C., Carter M., Lowery D., DeSilver D.A., Meanger J., Baulch-Brown C., Bennett M., Gaskell R.M. Nucleotide sequence of UK and Australian isolates of feline calicivirus (FCV) and phylogenetic analysis of FCVs. Vet. Microbiol. 1999, 67:175-193.
9. Hennet P.R., Camy G.A., McGahie D.M., Albouy M.V. Comparative efficacy of a recombinant feline interferon omega in refractory cases of calicivirus-positive cats with caudal stomatitis: a randomised, multi-centre, controlled, double-blind study in 39 cats. J. Feline Med. Surg. 2011, 13:577-587.
10. Hurley K.F., Sykes J.E. Update on feline calicivirus: new trends. Vet. Clin. North Am.: Small Anim. Pract. 2003, 33:759-772.
11. Kollaritsch H., Karbwang J., Wiedermann G., Mikolasek A., Na-Bangchang K., Wernsdorfer W. Mefloquine concentration profiles during prophylactic dose regimens. Wien. Klin. Wochenschr. 2000, 112:441-447.
12. Kreutz L.C., Seal B.S. The pathway of feline calicivirus entry. Virus Res. 1995, 35:63-70.
13. Lyon K.F. Gingivostomatitis. Vet. Clin. North Am.: Small Anim. Pract. 2005, 35:891-911.
14. McCann K.B., Lee A., Wan J., Roginski H., Coventry M.J. The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. J. Appl. Microbiol. 2003, 95:1026-1033.
15. McDonagh P., Sheehy P.A., Norris J.M. Identification and characterisation of small molecule inhibitors of feline coronavirus replication. Vet. Microbiol. 2014, 174:438-447.
16. Mochizuki M., Nakatani H., Yoshida M. Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro. Vet. Microbiol. 1994, 39:145-152.
17. Ninomiya H., Fukutome A., Kabayashi K., Shin Y., Uchino T., Motoyoshi S. Effect of recombinant feline interferon on feline calicivirus infection. XVI World Small Animal Veterinary Association 1991.
18. Ohe K., Takahashi T., Hara D., Hara M. Sensitivity of FCV to recombinant feline interferon (rFeIFN). Vet. Res. Commun. 2008, 32:167-174.
19. Owen A., Janneh O., Hartkoorn R.C., Chandler B., Bray P.G., Martin P., Ward S.A., Hart C.A., Khoo S.H., Back D.J. In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J. Pharmacol. Exp. Ther. 2005, 314:1202-1209.
20. Pedersen N.C., Elliott J.B., Glasgow A., Poland A., Keel K. An isolated epizootic of hemorrhagic-like fever in cats caused by a novel and highly virulent strain of feline calicivirus. Vet. Microbiol. 2000, 73:281-300.
21. Povey R.C. In vitro antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus. Am. J. Vet. Res. 1978, 39:175-178.
22. Radford A.D., Coyne K.P., Dawson S., Porter C.J., Gaskell R.M. Feline calicivirus. Vet. Res. 2007, 38:319-335.
23. Radford A.D., Dawson S., Coyne K.P., Porter C.J., Gaskell R.M. The challenge for the next generation of feline calicivirus vaccines. Vet. Microbiol. 2006, 117:14-18.
24. Shafer R., Vuitton D. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed. Pharmacother. 1999, 53:73-86.
25. Simpson J.A., Price R., ter Kuile F., Teja-Isavatharm P., Nosten F., Chongsuphajaisiddhi T., Looareesuwan S., Aarons L., White N.J. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin. Pharmacol. Ther. 1999, 66:472-484.
26. Smith A.W., Iversen P.L., O'Hanley P.D., Skilling D.E., Christensen J.R., Weaver S.S., Longley K., Stone M.A., Poet S.E., Matson D.O. Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection. Am. J. Vet. Res. 2008, 69:23-32.
27. Stuart A.D., Brown T.D.K. Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes. J. Virol. 2006, 80:7500-7509.
28. Taira O., Suzuki M., Takeuchi Y., Aramaki Y., Sakurai I., Watanabe T., Motokawa K., Arai S., Sato H., Maehara N. Expression of feline interferon-alpha subtypes in Esherichia coli, and their antiviral activity and animal species specificity. J. Vet. Med. Sci. 2005, 67:543-545.
29. Truyen U., Blewaska S., Schultheiss U. Antiviral potency of interferon-omega (IFN-omega) against selected canine and feline viruses. Prakt. Tierarzt 2002, 83:862-865.